Physician

Patrick J Ward, MD

According to 2025 Medicare claims, Patrick Ward, MD (NPI: 1093709297) practices medical oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Hamilton, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY CARE INC (NPI: 1790778041; TIN: 311106418) and primary practice location at 45242-5621. Ward is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Ward's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 371 traditional Medicare patients, billed 120,828 HCPCS/CPT codes, and received $2,257,357 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,197 prescription claims across 209 beneficiaries totaling $4,421,525 in drug costs, led by Verzenio (Abemaciclib). 2022 DME data shows 60 claims. Open Payments data shows 179 records totaling $528,036. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,067,850 to $2,257,357. Similarly, Part D prescription costs have risen steadily, from $554,059 to $4,421,525. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,306 and ending at $4,396.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	474	70,167	$1,067,850
2016	474	74,686	$928,038
2017	584	77,197	$1,013,304
2018	643	105,026	$1,737,723
2019	562	97,050	$1,911,160
2020	506	112,943	$2,486,812
2021	529	143,356	$2,626,026
2022	489	193,773	$3,586,965
2023	416	155,578	$3,042,191
2024	371	120,828	$2,257,357

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	776	$554,059
2016	166	863	$937,447
2017	186	992	$1,691,312
2018	180	1,021	$2,565,960
2019	178	1,005	$3,152,402
2020	180	1,230	$3,762,467
2021	190	1,146	$3,694,510
2022	207	1,160	$4,113,340
2023	212	1,161	$3,612,287
2024	209	1,197	$4,421,525

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	100	$5,716
2016	N/R	136	$6,089
2017	N/R	171	$6,965
2018	N/R	317	$12,694
2019	N/R	102	$6,823
2020	N/R	33	$2,253
2021	N/R	50	$3,959
2022	N/R	60	$4,210
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	86	347	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	171	271	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	200	362	$11
80053	Blood test, comprehensive group of blood chemicals	99	449	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	126	508	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	60	1,680	$906,017
Imbruvica	Ibrutinib	54	1,512	$848,030
Tagrisso	Osimertinib Mesylate	40	1,200	$653,685
Calquence	Acalabrutinib Maleate	27	810	$416,204
Erleada	Apalutamide	27	870	$398,424

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$7,559	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	159	$520,476	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Patrick J. Ward, MD?

Tedicare shows public-source Medicare data for Patrick J. Ward, MD (NPI 1093709297), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Patrick J. Ward, MD have ACO affiliation data?

Patrick J. Ward, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Patrick J. Ward, MD?

Patrick J. Ward, MD is linked to ONCOLOGY HEMATOLOGY CARE INC (billing NPI 1790778041) in the available physician profile data.

Does Patrick J. Ward, MD have Open Payments data?

Patrick J. Ward, MD has 179 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.